Status In progress
Process STA pre-2018
ID number 1140

Provisional Schedule

Expected publication 19 December 2018

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
14 September 2017 As you will be aware, the Department of Health has asked NICE to carry out a Single Technology Appraisal of pembrolizumab for untreated recurrent or metastatic squamous cell carcinoma of the head and neck. Following on from advice received from the company, the timelines for this appraisal are currently to be confirmed. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties when the situation changes.
28 June 2017 - 26 July 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
01 March 2017 Referral
01 March 2017 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance